Newer Stents Pose Dangers, 2 Doctors Say. That would be the drug eluting stents, now racking up a $6bn odd in US revenue for their manufacturers.
Well what did you expect? Oh, and by the way, still no evidence that stents are better than CABGs for the payer or the patient, in fact it’s still probably the other way around —as THCB has been saying for a while. But don’t expect much to change. After all you need more than evidence to stop this ball rolling downhill.
For example, I met someone with a new and better drug-eluting stent (from ex-BSX but now with Abbott) only last week, so if we decide that Cypher and Taxus aren’t the best answer, I’m sure the real answer will be something new—not something old.